Glenmark Pharma to Initiate Phase 2b Trial of atopic dermatitis drug
17 April 2018 | News
In addition to moderate-to-severe atopic dermatitis, the company is also evaluating the potential for conducting studies with GBR 830 for the treatment of other inflammatory autoimmune conditions
Drug major Glenmark Pharmaceuticals has announced initiation of phase 2b clinical trial of GBR 830, a novel investigational treatment for moderate-to-severe atopic dermatitis.
According to company, the trial's primary endpoint will assess the efficacy of GBR 830, compared to placebo. Secondary and exploratory trial endpoints include additional measures of efficacy, safety and pharmacodynamics.
Trial enrollment is expected to begin in June 2018, it added.
Glenmark said in addition to moderate-to-severe atopic dermatitis, the company is also evaluating the potential for conducting studies with GBR 830 for the treatment of other inflammatory autoimmune conditions.
Preparations for a clinical trial assessing GBR 830 for the treatment of systemic lupus erythematosus (SLE) are currently underway.
